Detection and Treatment of Ovarian Cancer by Targeting Tumor Extracellular Hydroxyapatite: A New Paradigm
Abstract
Our overall goal was to evaluate tumor microenvironment (TME) hydroxyapatite (HAP),Ca10(PO4)6OH2, as a potential imaging, prognostic, and therapeutic biomarker of ovarian cancer. We have shown that HAP-binding radiotracers such as FDA-approved 18F-NaF can be used with PET imaging and 99mTc-MDP with SPECT imaging to detect breast tumors; in this context, detection of tumor-associated HAP exhibited high specificity and a high signal-to-background ratio (SBR) as HAP is absent in normal soft tissue. In ovarian cancer, conventional imaging modalities lack clear metrics for assessing tumor burden before and after surgical debulking and for assessing tumor response to therapy. This is mainly due to lack of specificity and/or low SBR ratio from standard imaging. Additionally, we had developed a nanoparticulate sulfonated polystyrene solution, VU094562, to break-up HAP in vivo inducing localized alkalosis leading to tumor cell death.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2023
- Accession Number
- AD1216907
Entities
People
- Mohammed Tantawy
Organizations
- Vanderbilt University Medical Center